

Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology

Cyrus Kholdani, Wassim H. Fares, Vahid Mohsenin

Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, Connecticut, USA

Abstract: The development of pulmonary hypertension is a poor prognostic sign in patients with obstructive sleep apnea (OSA) and affects both mortality and quality of life. Although pulmonary hypertension in OSA is traditionally viewed as a result of apneas and intermittent hypoxia during sleep, recent studies indicate that neither of these factors correlates very well with pulmonary artery pressure. Human data show that pulmonary hypertension in the setting of OSA is, in large part, due to left heart dysfunction with either preserved or diminished ejection fraction. Longstanding increased left heart filling pressures eventually lead to pulmonary venous hypertension. The combination of hypoxic pulmonary vasoconstriction and pulmonary venous hypertension with abnormal production of mediators will result in vascular cell proliferation and aberrant vascular remodeling leading to pulmonary hypertension. These changes are in many ways similar to those seen in other forms of pulmonary hypertension and suggest shared mechanisms. The majority of patients with OSA do not receive a diagnosis and are undertreated. Appreciating the high prevalence and understanding the mechanisms of pulmonary hypertension in OSA would lead to better recognition and management of the condition.

Keywords: pulmonary hypertension, obstructive sleep apnea, heart failure, hypoxic vasoconstriction.

Pulm Circ 2015;5(2):220-227. DOI: 10.1086/679995.

Pulmonary hypertension (PH) is a hemodynamic and pathophysiological state that can be found in multiple clinical conditions. These have been classified by the World Health Organization (WHO) into five clinical groups with specific characteristics (Table 1).¹ WHO group 2 is the most common cause of PH in Western countries and is due to left heart disease—systolic and diastolic dysfunction and valvular disease.²⁻⁴ Obstructive sleep apnea (OSA) is commonly complicated by left heart disease and is associated with PH.⁴ OSA is a form of sleep-disordered breathing that is increasingly prevalent, in part due to the increasing rate of obesity and enhanced public awareness. An estimated 40 million Americans experience OSA, with a 3%–7% prevalence among men and a 2%–5% prevalence among women.⁵ OSA is an independent risk factor for systemic hypertension, stroke, myocardial ischemia, congestive heart failure, arrhythmias, and sudden cardiac death.⁶⁻¹¹ PH is present in 12%–34% of patients with OSA.¹²⁻¹⁵ However, the role of OSA in the development of PH and its mechanisms, independent of left ventricular failure, are not entirely clear. Patients with PH present with symptoms of dyspnea on exertion, fatigue, lightheadedness, chest pain, syncope, palpitations, and/or lower extremity edema.

When PH occurs as a consequence of OSA, however, symptoms may not be present because of obesity and a lack of physical exertion, or symptoms of PH may be overshadowed by those of other cardiovascular abnormalities. Nevertheless, it is paramount to con-

firm the presence of PH in patients with OSA for three reasons: (1) OSA is associated with a higher mortality among patients with PH than without PH, (2) a treatment modality specific to OSA should be formulated, and (3) the possible coexistence of another etiology of PH that may require a different management strategy should be determined. In this review, we discuss the epidemiology and pathophysiology of PH in the setting of OSA and its management strategies.

EPIDEMIOLOGY

Establishing the prevalence of PH due to OSA is challenging owing to the range of hemodynamic parameters and diagnostic tests used as well as the potential inclusion of patients with confounding diseases. In a large series of 220 consecutive subjects with OSA who had undergone right heart catheterization using a mean pulmonary artery pressure (Ppa) of >20 mmHg as diagnostic criterion for PH, Chaouat et al.¹² observed PH in 37 (17%) of 220 patients. However, of these 37 patients, 19 (51%) had pulmonary function testing demonstrating a forced expiratory volume in 1 s/forced vital capacity of <65%, indicative of obstructive lung disease. In a multiple regression analysis, PH was strongly linked to the presence of an obstructive (rather than restrictive) ventilatory pattern, hypoxemia, and hypercapnia in this cohort. To determine whether PH can be

Address correspondence to Dr. Vahid Mohsenin, 15 York Street, P.O. Box 208057, New Haven, CT 06520, USA. E-mail: vahid.mohsenin@yale.edu.

Submitted April 9, 2014; Accepted September 2, 2014; Electronically published April 8, 2015.

© 2015 by the Pulmonary Vascular Research Institute. All rights reserved. 2045-8932/2015/0502-0002. \$15.00.

Table 1

Updated clinical classification of pulmonary hypertension (PH),
Nice, France, 2013

1 PAH
1.1 Idiopathic PAH
1.2 Heritable PAH
1.2.1 BMPR2
1.2.2 ALK1, endoglin, SMAD9, CAV1, KCNK3
1.2.3 Unknown
1.3 Drugs and toxins induced
1.4 Associated with PAH
1.4.1 Connective tissue disease
1.4.2 Human immunodeficiency virus infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1' Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
1'' Persistent pulmonary hypertension of the newborn
2 Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
3 Pulmonary hypertension due to lung disease and/hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
4 Chronic thromboembolic pulmonary hypertension
5 Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH

Note: Adapted from Simonneau et al.¹ ALK1: activin-like receptor kinase-1; BMPR2: bone morphogenic protein receptor type II; CAV1: caveolin-1; KCNK3: a gene encoding potassium channel super family K member-3; PAH: pulmonary arterial hypertension; SMAD9: mothers against decapentaplegic 9.

present in OSA in the absence of hypoxic lung disease, Sajkov et al.¹⁶ studied 32 patients with OSA and found PH (estimated mean Ppa \geq 20 mmHg on Doppler echocardiography) in 34% of the subjects. Hetzel et al.¹⁷ studied 49 consecutive patients with OSA with normal pulmonary function testing and found six (12%) with resting PH using a mean Ppa $>$ 20 mmHg criterion on right heart catheterization. None had pathologically elevated pulmonary vascular resistance, and a majority had notable elevations in pulmonary artery occlusion pressure (PAOP), implicating left-sided heart disease as the mechanism of the PH.¹⁷ In a study involving 44 patients with OSA without chronic obstructive pulmonary disease (COPD) or left ventricular dysfunction, Bady et al.¹³ found PH (mean Ppa $>$ 20 mmHg and PAOP $<$ 15 mmHg) in 12 patients (27%).

The prevalence of sleep-disordered breathing in PH was investigated by several groups. Ulrich et al.¹⁸ observed sleep apnea, mainly central sleep apnea (CSA), in 17 (45%) of 38 patients with different etiologies of PH. The prevalence of OSA in patients with PAH and chronic thromboembolic PH (CTEPH) with New York Heart Association functional class II–III without COPD or left ventricular dysfunction was 89%.¹⁹ In a study of 169 patients with PAH, 45 patients (26.6%) had an apnea–hypopnea index (AHI) $>$ 10 events/h. Of these, 27 patients (16%) had OSA, and 18 patients (10.6%) had CSA.²⁰ Among 28 patients with idiopathic PAH, 7% had OSA and 14% had CSA.²⁰

All in all, patients with PH of various etiologies have high prevalence of OSA. Likewise, patients with OSA are also at increased risk of having PH.¹⁵ In general, 27%–30% of patients with OSA without left ventricular dysfunction or hypoxemic lung disease have PH.^{13,16} A conservative estimate of the overall prevalence of PH associated with OSA in the United States is 2.5 million cases. Of importance is that the patients with OSA and PH have lower quality of life²¹ and higher mortality than those without PH.²²

PATHOPHYSIOLOGY

Structure and function of the pulmonary circulation under normal conditions

Anatomically, the pulmonary circulation is divided into arteries, arterioles, capillaries, venules, and veins. The pulmonary circulation is a low-resistance system with the normal Ppa systolic/diastolic being \approx 25/8 mmHg compared with 120/70 mmHg for the systemic circulation, with similar blood flow. The main pulmonary artery has smaller wall thickness and less organized elastic lamina despite having the same size as the main aorta. The capillary system that is not in contact with alveoli has basement membranes that are not fused and has more collagen, proteoglycan matrix, and fibroblasts, some of which may contain actin-myosin complex. Pulmonary circulation is almost always dilated with negligible resting tone and low resistance and hence would not be able to dilate further, as evident by the lack of vasodilatory response to inhaled nitric oxide (NO) in those subjects breathing air,²³ which indicates that the only regulation is by vasoconstriction. Increased cardiac output during exercise is accommodated by recruitment of vessels, thereby increasing the size of the vascular bed. The later mechanism can keep the pressure low in spite of marked increase in flow.

Structure and function of the pulmonary circulation under abnormal conditions

The reduction in alveolar oxygen tension, such as in low ventilation/perfusion units (high altitude, lung parenchymal, or airway disease), can lead to pulmonary vasoconstriction. Depending on the magnitude of the alveolar hypoxia (focal vs. global), pulmonary vascular resistance can increase by up to 300%.²⁴ Hypercapnia and acidosis, which independently cause pulmonary vasoconstriction, tend to augment the effect of hypoxic pulmonary vasoconstriction.^{25,26} Differential lung ventilation of normal human subjects with hypoxic gas decreases blood flow to the same lung by 22% through hypoxic vasoconstriction, shifting the blood flow to the normoxic lung. However, redistribution of blood flow is not powerful enough to overcome the gravitational effects of blood diversion from the upper lung to the lower lung in the lateral decubitus position.^{27,28} Hypoxic pulmonary vasoconstriction, although regarded as a physiological process that preserves systemic oxygenation, is also regarded as a pathophysiological entity predisposing to heightened pulmonary artery tones and subsequent PH.²⁹ Wu and colleagues³⁰ have shown that, although acute hypoxia (partial pressure of oxygen, 25–30 mmHg for 5–10 minutes) stimulates a reduction in reactive oxygen species (ROS), chronic hypoxia (48 hours) actually increases ROS production in human pulmonary artery smooth muscle cells. This points to a potential difference at the subcellular level response to acute and chronic hypoxia, which may explain the phenotypical changes seen in acute hypoxia (vasoconstriction) and chronic hypoxia (vascular remodeling). Acute hypoxia constricts precontracted human pulmonary artery rings in a manner that is dependent on the presence of the endothelium, because denuding the endothelium resulted in a markedly reduced hypoxic vasoconstrictive response.³¹ Because NO is a potent vasodilator, endothelial NO synthase (eNOS) inhibition would logically suggest that the vasoconstriction-vasodilation balance may be shifted in chronic hypoxia toward constriction by reducing NO production. Chronic hypoxia is associated with an increase in Rho kinase A expression with a simultaneous decrease in eNOS messenger RNA and protein expression in human pulmonary endothelial cells.³² However, there is a compensatory mechanism by increasing inducible NOS and NO production of human pulmonary endothelial cells.^{33,34} Key regulators of vascular remodeling in response to chronic hypoxia include the Rho GTPase family of proteins, which are involved in cell adhesion, migration, and proliferation.³⁵ Native inhabitants of Peru are often born with right ventricular hypertrophy and elevated resting Ppas; those children who remain at sea level demonstrate a rapid reversal of these phenomena, whereas those who remain at high altitudes show little regression of these characteristics.³⁶ Autopsy of these individuals revealed that the PH was likely attributable to the thickening of the muscular layers of the pulmonary arterial tree.³⁷ These investigators measured arterial partial pressure of oxygen and saturation in these inhabitants and concluded that there was a direct causal relationship between hypoxia and PH.

MECHANISMS OF PH IN OSA

The majority of patients with OSA experience cyclical oxygen desaturations during sleep. These episodes can last from 10 seconds

to more than 40 seconds several times an hour followed by arousals and complete or partial recovery of oxygen saturation. The cumulative effect of intermittent hypoxia can lead to polycythemia and PH. Most patients with OSA have normal oxygen saturation while awake, with the exception of those patients who also have obesity hypoventilation syndrome or underlying lung disease. Patients with obesity hypoventilation syndrome are at greater risk of having PH due to the additional effect of hypercapnia, with a prevalence 59% greater than that among those with OSA alone.^{21,38} Based on several studies, the average prevalence of PH among those with OSA is approximately 20%. This is in contrast to the prevalence of systemic hypertension, which can be as much as 60%. As a result of the high frequency of diurnal hypertension and intermittent surges in arterial blood pressure due to respiratory events during sleep,³⁹ patients with OSA have high prevalence of left ventricular hypertrophy⁴⁰ and dysfunction.^{41–43} Left ventricular dysfunction accounts for a large proportion of PH in patients with OSA.^{17,22} However, PH and right heart failure can develop in patients with OSA with preserved left ventricular ejection fraction.⁴⁴ The prevalence of PH in heart failure with preserved left ventricular ejection fraction was in the range of 52% (defined as mean Ppa >25 mmHg by right heart catheterization).⁴⁵ This was comparable to 62% in a cohort of 379 patients with heart failure with reduced ejection fraction, who had a mean Ppa >20 mmHg by right heart catheterization.⁴⁶ Mitral valve disease-associated PH shares some features with the PH seen in OSA—elevated left atrial filling pressure—in the presence of either diastolic or systolic left ventricular dysfunction. In a study of nine patients with mitral regurgitation and PH undergoing valve replacement, Du et al.⁴⁷ demonstrated pulmonary vascular changes similar to idiopathic PAH in the form of proliferation of vascular smooth-muscle cells and asymmetric neointimal hyperplasia in small pulmonary arteries and arterioles. These observations suggest that initial pulmonary venous hypertension due to left ventricular dysfunction can lead to PH indistinguishable from the idiopathic PAH form and further suggest shared cellular and molecular pathways in the pathogenesis of PH. Mathematical models exploring this paradigm demonstrate that there is an initial passive increase in pulmonary blood volume secondary to the hydrostatic forces resulting from heart failure with either reduced or preserved systolic function.⁴⁴ The result of this initial insult is a passive postcapillary PH with a normal transpulmonary pressure gradient and, consequently, relatively normal pulmonary vascular resistance. In addition to this pressure-dependent mechanism, hypoxia-sensitive inflammatory and proliferative pathways may be involved in the development of PH in OSA.⁴⁸ Animal models have clearly demonstrated that brief, repetitive exposure to hypoxemia over a duration of just a few weeks, a situation akin to intermittent hypoxia in OSA, is sufficient to cause pulmonary arteriolar remodeling and right ventricular hypertrophy.^{49,50} In a recent study, Sheikh et al.⁵¹ demonstrated that exposure of mice to 10% hypoxia for 3 weeks resulted in muscularization of distal pulmonary arterioles.

In experiments in which mice were exposed to chronic intermittent hypoxia for 8 weeks, the induced PH was associated with increased lung levels of the NADPH oxidase subunits, Nox4 and p22phox, as well as increased activity of platelet-derived growth factor receptor β and its associated downstream effector, protein

kinase B (the latter is involved in apoptosis, cell proliferation, transcription, and cell migration).⁵² NADPH oxidase is an important source of superoxide production in the vasculature. Superoxide generation in the vascular wall is a well-recognized stimulus for vascular wall cell proliferation and vasoconstriction.⁵³ These chronic intermittent hypoxia-induced derangements were attenuated in similarly treated gp91phox knockout mice with disabled NADPH oxidase system, suggesting that NADPH oxidase-derived ROS contribute to the development of pulmonary vascular remodeling and hypertension caused by chronic intermittent hypoxia.⁵²

Several studies have implicated involvement of serotonin in the etiology of PH.^{54,55} A study by Launay et al.⁵⁶ showed that hypoxia-induced PAH in mice was associated with an increase in serotonin and its receptor expression, resulting in serotonin-dependent vascular remodeling. As a potent pulmonary vasoconstrictor, serotonin, released from pulmonary neuroendocrine cells and neuroepithelial bodies, might have a dual effect on pulmonary circulation, contributing to both hypoxia-induced acute vasoconstriction and chronic vascular remodeling by activating its cognate receptors.

Angiopoietin-1 (Ang-1) originating from vascular smooth muscle cells is an endothelial selective receptor tyrosine kinase (Tie2) agonist that stabilizes the development of newly formed blood vessels and promotes quiescence and structural integrity of mature vessels.⁵⁷ Hypoxia disrupts the constitutive Ang-1–Tie2 signaling by preventing Ang-1 from binding to the receptor. Consequently, loss of Tie2 signaling destabilizes the endothelium and induces an angiogenic response in the presence of vascular endothelial growth factor.⁵⁸ Human lungs from patients with nonfamilial PH of various causes, including mitral valve stenosis-associated PH, show high expression of Ang-1 in the smooth muscle cell lining of small pulmonary vessels and tyrosine phosphorylation of the Tie2 receptor in pulmonary vascular endothelium. These data led the authors to conclude that all forms of PH are linked by defects in the signaling pathway involving Ang-1 and Tie2.⁴⁷ The role of the Ang-1–Tie2 ligand-receptor system in the pathogenesis of PH is controversial. Other studies using transgenic mice models with overexpression of Ang-1 had shown a protective effect in monocrotaline-induced PH.^{59,60} Furthermore, serum levels of Ang-1 had an inverse correlation with pulmonary systolic pressure in patients with mitral stenosis.⁶¹ Because biological roles of angiopoietins may depend on the presence of other angiogenic growth factors, the functional significance of the Ang-1–Tie2 system may be different in various pathophysiological conditions of PH. It is not known whether dysregulation of the Ang-1–Tie2 system is operative in PH associated with OSA. However, the findings that hypoxia or left heart dysfunction (mitral stenosis) are associated with pulmonary vascular remodeling will make Ang-1–Tie2 system involvement in OSA plausible.

Endothelin-1 (ET-1) is a member of a family of peptides produced primarily by the endothelium with a key regulatory role in vascular homeostasis and has potent vasoconstrictor properties. In the pulmonary arteries of rats exposed to chronic intermittent hypoxia, ET-1 expression was increased, and ET-1 more potently elicited constriction of the pulmonary artery due to increased expression of ETA receptors compared with normoxic rats.⁶² In these animals, exposure to chronic intermittent hypoxia induced marked endothelial cell damage associated with a functional decrease of

endothelium-dependent vasodilation in the pulmonary artery.⁶² Plasma levels of ET-1 are elevated in several forms of PH.^{63,64} Individuals with PH due to left ventricular dysfunction demonstrate vasodilation of pulmonary vasculature with infusion of sitaxsentan, a selective ET_A receptor antagonist, that is not seen in controls, which suggests a contributing role of ET-1 in PH related to left heart dysfunction.⁶⁵ However, endothelin receptor antagonists have not been proven to be beneficial in clinical trials involving patients with left heart dysfunction.^{66,67} The role of endothelin in PH of OSA is not known. Circulating levels of ET-1 in patients with OSA are no different from those in control subjects.^{68,69} In view of the effect of endothelin on the pulmonary vasculature in models of intermittent hypoxia and left heart dysfunction, it is conceivable that it might play a role in some patients with OSA and PH. Additional studies are needed to investigate the role of endothelin in PH of OSA.

NO is a potent vasodilator of pulmonary and systemic circulation. It is generated by the enzymatic action of NO synthase on L-arginine in endothelial cells, and the gaseous NO acts on soluble guanylate cyclase in vascular smooth muscle cells to generate cyclic guanosine monophosphate (cGMP), causing vasodilation. Chronic intermittent hypoxia causes suppression of eNOS and impairment of endothelial-dependent vasodilation by an NF- κ B-dependent mechanism.⁷⁰ In humans with OSA, alveolar NO is reduced.⁷¹ Furthermore, circulating cGMP is reduced in patients with OSA with endothelial dysfunction.⁷² Riociguat, a stimulator of soluble guanylate cyclase-increasing cGMP, has recently been approved by the US Food and Drug Administration on the basis of its efficacy in preclinical and clinical trials of PAH (and in CTEPH), supporting the role of NO-cGMP system dysregulation in PAH and OSA.^{73,74}

Obesity, through metabolic dysregulation and vascular inflammation, is associated with increased risk of PAH, independent of OSA and left heart dysfunction.⁷⁵ Adiponectin is secreted from adipose tissues and has anti-inflammatory and vascular homeostatic functions.⁷⁶ Circulating levels of adiponectin are decreased in individuals with obesity and OSA.^{77,78} Given the known effects of adiponectin on pulmonary vascular inflammation and remodeling,^{79,80} it seems likely that relative deficiency of adiponectin, as seen in obesity and OSA, could be an important mechanistic link between OSA and PH.

In summary, the mechanisms of PH in OSA are multifactorial and due to both increased left heart pressures and hypoxia-related processes with involvement of numerous pathways involving ROS, perturbation of NO, angiogenic factors, and vasoactive agents, resulting in partially reversible vasoconstriction and increased Ppa (Fig. 1).

DIAGNOSTIC CONSIDERATIONS

The evaluation process for a patient with suspected PH requires a series of investigations intended to confirm the diagnosis, which is best done in a multidisciplinary pulmonary vascular center. The details of the workup for patients with suspected PH is beyond the scope of this review.^{1,81} However, the key studies will be discussed here. Patients with PH present with symptoms of dyspnea, lightheadedness on exertion, fatigue, chest pain, syncope, palpitations, and/or lower extremity edema. Transthoracic echocardiography




Figure 1. Obstructive sleep apnea (OSA) causes pulmonary hypertension through hypoxia pathway with activation of vasoactive factors and hydrostatic mechanism due to increase in left atrial pressure leading to pulmonary venous hypertension. Both pathways eventually cause vascular remodeling, pulmonary arterial hypertension, and right heart dysfunction. LVEDP: left ventricular end-diastolic pressure; NADPH: nicotinamide adenine dinucleotide phosphate; ROS: reactive oxygen species.

provides several variables that correlate with right heart hemodynamics, including estimated pulmonary arterial systolic pressure, and should always be performed in the case of suspected PH as a screening modality. A systematic review and meta-analysis of 29 studies with a total patient population of 1,998 demonstrated an overall correlation coefficient of 0.7 (95% confidence interval [CI], 0.67–0.73) for estimated systolic Ppa between color Doppler echocardiography (tricuspid regurgitant jet method) and right heart catheterization, with a sensitivity and specificity of 83% (95% CI, 73%–90%) and 72% (95% CI, 53%–85%), respectively.⁸² Of note, the agreement between Doppler echocardiography and right heart catheterization data was similar at both mild and moderately elevated systolic pulmonary arterial pressure values. Furthermore, echocardiography is a useful and noninvasive modality not only for estimating pulmonary pressure but also for determining underlying anatomical and functional cardiac abnormalities in patients with suspected PH. However, the diagnosis of PH and the assessment of vasodilatory capacity of pulmonary vasculature require right heart catheterization. Other diagnostic tests may include serologic testing for collagen vascular diseases, pulmonary function tests, chest imaging, ventilation-perfusion scanning, and arterial blood gases

for underlying pulmonary diseases. There are no formal guidelines for routine sleep study in patients with PH; however, in view of the high prevalence of nocturnal hypoxemia and OSA in PH, patients with PH should be screened for sleep-disordered breathing by sleep study.¹⁹

EFFECT OF TREATMENT OF OSA ON PH

In one of the first studies of the effect of continuous positive airway pressure (CPAP) treatment on pulmonary hemodynamics in OSA, Sforza et al.⁸³ evaluated seven patients with PH with right heart catheterization before and after 1 year of CPAP treatment. Despite some improvement in oxygen saturation, mean Ppa did not change. A decade later, Alchanatis et al.¹⁴ examined the effect of CPAP therapy in six patients with OSA and PH diagnosed on echocardiography and confirmed by right heart catheterization with normal PAOP values. After more than 6 months of CPAP therapy, there was a significant reduction in mean Ppa value from 25.6 ± 4.0 mmHg to 19.5 ± 1.6 mmHg ($P < 0.001$).¹⁴ In a prospective study involving 22 patients with OSA (mean AHI, 48.6 ± 5.2 events/h), five of whom had mean Ppa ≥ 20 mmHg, 4 months of CPAP treatment decreased mean Ppa from 17.0 ± 1.2 mmHg to 14.5 ± 0.8 mmHg in the entire group ($P < 0.05$). The greatest treatment effects occurred in the five patients who had PH at baseline. The reduction in mean Ppa was attributed to decreased pulmonary vascular resistance and decreased vasoconstrictive response to hypoxic stimulus.⁸⁴ In a randomized, sham-controlled crossover study involving 10 patients with OSA and PH (right ventricular systolic pressure [RVSP] > 30 mmHg estimated by Doppler echocardiograph) and no known cardiac or lung diseases, 12 weeks of CPAP therapy decreased RVSP from 28.8 ± 7.9 mmHg to 24.0 ± 5.8 mmHg ($P < 0.0001$). Higher reduction in RVSP after effective CPAP therapy was observed in patients with OSA with either left ventricular diastolic dysfunction (change, 7.3 ± 3.3 mmHg vs. 1.6 ± 1.8 mmHg in those without left ventricular diastolic dysfunction; $P < 0.001$) or presence of PH at baseline (change, 8.5 ± 2.8 mmHg vs. 2.6 ± 2.8 mmHg in those without PH at baseline; $P < 0.001$).⁸⁵ CPAP therapy for 6–24 months improved right ventricular ejection fraction estimated by nuclear ventriculography, which increased from $30\% \pm 3\%$ to $39\% \pm 3\%$ ($P = 0.01$).⁸⁶ Some of the inconsistency of response to CPAP may have been due to small sample size and lack of more detailed characterization of the etiology of PH in OSA in terms of presence or absence of left and right heart dysfunction and other confounding factors, such as underlying lung disease. Of note, there is insufficient anthropomorphic data from the aforementioned studies, which would suggest that some component of the hemodynamic improvements conferred by CPAP therapy was attributable to other factors, such as concurrent weight loss. We recommend treatment of mild-to-moderate PH with OSA-specific therapy and consideration for addition of pharmacotherapy in those with severe PH.

SUMMARY

PH is prevalent in OSA and is commonly associated with left ventricular dysfunction. Pulmonary vascular changes are due to both

hypoxic vasoconstriction and vascular remodeling. PH tends to improve with the treatment of OSA, and the more severe the PH the greater the response to CPAP. However, treatment of OSA may not completely resolve PH. These patients should be evaluated for other etiologies and considered for pharmacologic therapy.

Source of Support: Nil.

Conflict of Interest: None declared.

REFERENCES

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2013;62:D34–D41.
2. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. *Clin Chest Med* 2007;28:233–241.
3. Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. *Heart* 2012;98:1805–1811.
4. Hansdottir S, Groskreutz DJ, Gehlbach BK. WHO's in second?: a practical review of World Health Organization group 2 pulmonary hypertension. *Chest* 2013;144:638–650.
5. Punjabi NM. The epidemiology of adult obstructive sleep apnea. *Proc Am Thorac Soc* 2008;5:136–143.
6. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 2000;342:1378–1384.
7. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med* 2005;353:2034–2041.
8. Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. *Sleep* 2009;14:131–136.
9. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawab R, Kirchner HL, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health study. *Am J Respir Crit Care Med* 2006;173:910–916.
10. Peled N, Abinader EG, Pillar G, Sharif D, Lavie P. Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. *J Am Coll Cardiol* 1999;34:1744–1749.
11. Gami AS, Olson EJ, Shen WK, Wright RS, Ballman KV, Hodge DO, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. *J Am Coll Cardiol* 2013;62:610–616.
12. Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome: results in 220 consecutive patients. *Chest* 1996;109:380–386.
13. Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. *Thorax* 2000;55:934–939.
14. Alchanatis M, Tourkhoriti G, Kakouros S, Kosmas E, Podaras S, Jordanoglou JB. Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. *Respiration* 2001;68:566–572.
15. Sajkov D, McEvoy RD. Obstructive sleep apnea and pulmonary hypertension. *Prog Cardiovasc Dis* 2009;51:363–370.
16. Sajkov D, Wang T, Saunders NA, Bune AJ, Neill AM, Douglas Mcevoy R. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. *Am J Respir Crit Care Med* 1999;159:1518–1526.
17. Hetzel M, Kochs M, Marx N, Woehrle H, Mobarak I, Hombach V, et al. Pulmonary hemodynamics in obstructive sleep apnea: frequency and causes of pulmonary hypertension. *Lung* 2003;181:157–166.
18. Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. *Chest* 2008;133:1375–1380.
19. Jilwan FN, Escourrou P, Garcia G, Jaïs X, Humbert M, Roisman G. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. *Chest* 2013;143:47–55.
20. Dumitrascu R, Tiede H, Eckermann J, Mayer K, Reichenberger F, Ghofrani HA, et al. Sleep apnea in precapillary pulmonary hypertension. *Sleep Med* 2013;14:247–251.
21. Kauppert CA, Dvorak I, Kollert F, Heinemann F, Jorres RA, Pfeifer M, et al. Pulmonary hypertension in obesity-hypoventilation syndrome. *Respir Med* 2013;107:2061–2070.
22. Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. *Am J Cardiol* 2009;104:1300–1306.
23. Frostell CG, Blomqvist H, Hedenstierna G, Lundberg J, Zapol WM. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. *Anesthesiology* 1993;78:427–435.
24. Bartsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. *N Engl J Med* 1991;325:1284–1289.
25. Enson Y, Giuntini C, Lewis ML, Morris TQ, Ferrer MI, Harvey RM. The influence of hydrogen ion concentration and hypoxia on the pulmonary circulation. *J Clin Invest* 1964;43:1146–1162.
26. Bergofsky EH, Haas F, Porcelli R. Determination of the sensitive vascular sites from which hypoxia and hypercapnia elicit rises in pulmonary arterial pressure. *Fed Proc* 1968;27:1420–1425.
27. Arborelius M Jr, Lundin G, Svanberg L, Defares JG. Influence of unilateral hypoxia on blood flow through the lungs in man in lateral position. *J Appl Physiol* 1960;15:595–597.
28. Defares JG, Lundin G, Arborelius M Jr, Stromblad R, Svanberg L. Effect of unilateral hypoxia on pulmonary blood flow distribution in normal subjects. *J Appl Physiol* 1960;15:169–174.
29. Preston IR. Clinical perspective of hypoxia-mediated pulmonary hypertension. *Antioxid Redox Signal* 2007;9:711–721.
30. Wu W, Platoshyn O, Firth AL, Yuan JX. Hypoxia divergently regulates production of reactive oxygen species in human pulmonary and coronary artery smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* 2007;293:L952–L959.
31. Demiryurek AT, Wadsworth RM, Kane KA, Peacock AJ. The role of endothelium in hypoxic constriction of human pulmonary artery rings. *Am Rev Respir Dis* 1993;147:283–290.
32. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. *Circulation* 2002;106:57–62.
33. Beleslin-Cokic BB, Cokic VP, Wang L, Piknova B, Teng R, Schechter AN, et al. Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells. *Cytokine* 2011;54:129–135.
34. Krotova K, Patel JM, Block ER, Zharikov S. Hypoxic upregulation of arginase II in human lung endothelial cells. *Am J Physiol Cell Physiol* 2010;299:C1541–C1548.
35. Yu L, Quinn DA, Garg HG, Hales CA. Heparin inhibits pulmonary artery smooth muscle cell proliferation through guanine nucleotide exchange factor-H1/RhoA/Rho kinase/p27. *Am J Resp Cell Mol Biol* 2011;44:524–530.
36. Penalzoa D, Sime F, Bancharo N. Pulmonary hypertension in healthy man born and living at high altitude: Fifth Aspen Lung Conference: normal and abnormal pulmonary circulation. *Med Thorac* 1962;19:449–460.
37. Arias-Stella J, Recavarren S. Right ventricular hypertrophy in native children living at high altitude. *Am J Pathol* 1962;41:55–64.
38. Kessler R, Chaouat A, Schinkewitch P, Faller M, Casel S, Krieger J, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. *Chest* 2001;120:369–376.

39. Boysen PG, Block AJ, Wynne JW, Hunt LA, Flick MR. Nocturnal pulmonary hypertension in patients with chronic obstructive pulmonary disease. *Chest* 1979;76:536–542.
40. Hedner J, Ejnell H, Caidahl K. Left ventricular hypertrophy independent of hypertension in patients with obstructive sleep apnoea. *J Hypertens* 1990;8:941–946.
41. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. *Eur J Heart Fail* 2009;11:602–608.
42. Chami HA, Devereux RB, Gottdiener JS, Mehra R, Roman MJ, Benjamin EJ, et al. Left ventricular morphology and systolic function in sleep-disordered breathing: the Sleep Heart Health study. *Circulation* 2008;117:2599–2607.
43. Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health study. *Circulation* 2010;122:352–360.
44. Segers VF, Brutsaert DL, De Keulenaer GW. Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction: pathophysiology and natural history. *Curr Opin Cardiol* 2012;27:273–280.
45. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. *J Am Coll Cardiol* 2009;53:1119–1126.
46. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. *J Am Coll Cardiol* 2001;37:183–188.
47. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, et al. Signaling molecules in nonfamilial pulmonary hypertension. *N Engl J Med* 2003;348:500–509.
48. Voelkel NF, Mizuno S, Bogaard HJ. The role of hypoxia in pulmonary vascular diseases: a perspective. *Am J Physiol Lung Cell Mol Physiol* 2013;304:L457–L465.
49. McGuire M, Bradford A. Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats. *Eur Respir J* 2001;18:279–285.
50. Campen MJ, Shimoda LA, O'Donnell CP. Acute and chronic cardiovascular effects of intermittent hypoxia in C57BL/6J mice. *J Appl Physiol* (1985) 2005;99:2028–2035.
51. Sheikh AQ, Lighthouse JK, Greif DM. Recapitulation of developing artery muscularization in pulmonary hypertension. *Cell Rep* 2014;6:809–817.
52. Nisbet RE, Graves AS, Kleinhenz DJ, Rupnow HL, Reed AL, Fan TH, et al. The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. *Am J Resp Cell Mol Biol* 2009;40:601–609.
53. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. *Am J Physiol Regul Integr Comp Physiol* 2004;287:R1014–R1030.
54. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. *Thorax* 1999;54:161–168.
55. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. *Br J Pharmacol* 2000;131:161–168.
56. Launay JM, Herve P, Peoch K, Tournois C, Callebort J, Nebigil CG, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. *Nat Med* 2002;8:1129–1135.
57. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. *Nat Rev Mol Cell Biol* 2009;10:165–177.
58. Pichiule P, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. *J Biol Chem* 2004;279:12171–12180.
59. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ. Protective role of angiopoietin-1 in experimental pulmonary hypertension. *Circ Res* 2003;92:984–991.
60. Kugathasan L, Ray JB, Deng Y, Rezaei E, Dumont DJ, Stewart DJ. The angiopoietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice. *J Exp Med* 2009;206:2221–2234.
61. Karapinar H, Esen O, Emiroglu Y, Akcakoyun M, Pala S, Kargin R, et al. Serum levels of angiopoietin-1 in patients with pulmonary hypertension due to mitral stenosis. *Heart Vessels* 2011;26:536–541.
62. Wang Z, Li AY, Guo QH, Zhang JP, An Q, Guo YJ, et al. Effects of cyclic intermittent hypoxia on ET-1 responsiveness and endothelial dysfunction of pulmonary arteries in rats. *PLoS One* 2013;8:e58078.
63. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. *Circulation* 1992;85:504–509.
64. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. *Circulation* 1991;84:2280–2285.
65. Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. *Circulation* 2002;106:1618–1621.
66. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. *J Card Fail* 2005;11:12–20.
67. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension—a multicenter randomized study. *Cardiology* 2008;109:273–280.
68. Moller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. *Am J Hypertens* 2003;16:274–280.
69. Mohsenin V, Urbano F. Circulating antiangiogenic proteins in obstructive sleep apnea and hypertension. *Respir Med* 2011;105:801–807.
70. Wang B, Yan B, Song D, Ye X, Liu SF. Chronic intermittent hypoxia down-regulates endothelial nitric oxide synthase expression by an NF- κ B-dependent mechanism. *Sleep Med* 2012;14:165–171.
71. Foresi A, Leone C, Olivieri D, Cremona G. Alveolar-derived exhaled nitric oxide is reduced in obstructive sleep apnea syndrome. *Chest* 2007;132:860–867.
72. Jafari B, Mohsenin V. Activation of heme oxygenase and suppression of cGMP are associated with impaired endothelial function in obstructive sleep apnea with hypertension. *Am J Hypertens* 2012;25:854–861.
73. Schwappacher R, Kilic A, Kojonazarov B, Lang M, Diep T, Zhuang S, et al. A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension. *J Biol Chem* 2013;288:16557–16566.
74. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med* 2013;369:330–340.
75. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. *Mayo Clin Proc* 2011;86:105–112.
76. Hansmann G, Rabinovitch M. The protective role of adiponectin in pulmonary vascular disease. *Am J Physiol Lung Cell Mol Physiol* 2009;298:L1–L2.
77. Vatanserver E, Surmen-Gur E, Ursavas A, Karadağ M. Obstructive sleep apnea causes oxidative damage to plasma lipids and proteins and decreases adiponectin levels. *Sleep Breath* 2010;15:275–282.

78. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. *Biochem Biophys Res Commun* 2012;425:560–564.
79. Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, Raheer MJ, et al. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. *Am J Resp Cell Mol Biol* 2009; 41:397–406.
80. Summer R, Fiack CA, Ikeda Y, Sato K, Dwyer D, Ouchi N, et al. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. *Am J Physiol Lung Cell Mol Physiol* 2009;297:L432–L438.
81. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiéry JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2009;30:2493–2537.
82. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. *Heart* 2011;97:612–622.
83. Sforza E, Krieger J, Weitzenblum E, Apprill M, Lampert E, Ratamaharo J. Long-term effects of treatment with nasal continuous positive airway pressure on daytime lung function and pulmonary hemodynamics in patients with obstructive sleep apnea. *Am Rev Resp Dis* 1990;141:866–870.
84. Sajkov D, Wang T, Saunders NA, Bune AJ, McEvoy RD. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. *Am J Respir Crit Care Med* 2002;165:152–158.
85. Arias MA, Garcia-Rio F, Alonso-Fernandez A, Martinez I, Villamor J. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. *Eur Heart J* 2006;27:1106–1113.
86. Nahmias J, Lao R, Karetzky M. Right ventricular dysfunction in obstructive sleep apnoea: reversal with nasal continuous positive airway pressure. *Eur Respir J* 1996;9:945–951.